AML is difficult to treat due to a combination of biological heterogeneity and patient-related risk factors such as age or co-morbidities, resulting in poor long-term overall survival.23 Targeting of surface markers, such as CD47, promises a novel therapeutic approach in AML. Here, CD47 is linked to acute myeloid leukemia.